Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
PHI and Boston Children’s Hospital enter evaluation agreement
PHI and Boston Children’s Hospital – a Harvard Medical School teaching hospital – have signed an agreement to evaluate PHI’s HoloMonitor®technology for applications in cell-based cancer research.
PHI and Boston Children’s Hospital enter evaluation agreement
Big Pharma company orders third HoloMonitor
HoloMonitor provide vital information to development of improved child cancer treatment
PHI achieves market acceptance goals
Prior to the company’s IPO in early 2014, three market acceptance goals were set out to be achieved by the end of 2015: 50 units in operation at customers and key opinion leaders, collaboration agreements with 8 key opinion leaders and the company’s main product HoloMonitor® M4 shall be manufactured in series production.
PHI invited to speak at world leading scientific event
Big Pharma embraces HoloMonitor technology from PHI
Upon completion of an extensive evaluation in early September one of the top pharmaceutical companies in the world has decided to acquire two HoloMonitor® instruments. The ordered configuration is an automated version of the HoloMonitor platform.
HoloMonitor technology help researchers fight ovarian cance
Ovarian cancer is one of the deadliest forms of cancer. Researchers at the Center of Excellence for Holographic Imaging at Northeastern University in Boston have used HoloMonitor technology to study how the immune system can be stimulated to fight this deadly cancer form. The research results have been published in Journal of Clinical & Cellular Immunology.